Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate

OBJECTIVE: The aim of this study was to evaluate the safety of 3-monthly paliperidone palmitate (PP3M) vs once-monthly paliperidone palmitate (PP1M) treatment with regard to extrapyramidal symptom (EPS)-related treatment-emergent adverse events (TEAEs) in patients with schizophrenia, previously stab...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathews, Maju, Nuamah, Isaac, Savitz, Adam J, Hough, David W, Najarian, Dean, Kim, Edward, Gopal, Srihari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207222/
https://www.ncbi.nlm.nih.gov/pubmed/30498351
http://dx.doi.org/10.2147/NDT.S175364

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207222/
https://www.ncbi.nlm.nih.gov/pubmed/30498351
http://dx.doi.org/10.2147/NDT.S175364

Ejemplares similares